Method for producing triazine compound

Patent metadata

Field	Value
Publication number	US-2021380541-A1
Application number	US-201716464562-A
Country	US
Kind code	A1
Filing date	Nov 29, 2017
Priority date	Nov 30, 2016
Publication date	Dec 9, 2021
Grant date	—

Abstract

The present invention provides an industrially advantageous method for producing a 3,5-disubstituted triazine compound that is useful as an active pharmaceutical ingredient. More specifically, the present invention provides a production method, whereby it becomes possible to efficiently produce a 3-oxo-5-substituted triazine in water without the need to isolate an intermediate that may have mutagenicity, and it also becomes possible to perform the production without the need to isolate a product in each of multiple steps. Namely, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of reacting a compound represented by the following formula IV or a salt thereof with a base in water, and optionally including a step of forming a salt thereof. Specifically, the present invention provides a method for producing a compound represented by formula I or a salt thereof, the method including a step of derivatizing a compound represented by formula II or a salt thereof into a corresponding compound represented by formula III, a salt thereof, or a derivative thereof, then a step of reacting the resulting compound, a salt thereof, or a derivative thereof with aminourea or a salt thereof in water to produce a compound represented by formula IV or a salt thereof, and then a step of reacting the resulting compound or a salt thereof in the presence of a base.

(wherein ring A represents an optionally substitued aryl group or an optionally substituted heteroaryl group)

First claim

1 . A method for producing a compound represented by formula I:

(wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group) or a salt thereof, said method comprising a step of reacting a compound represented by formula IV:

(wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group) or a salt thereof with a base in water, and optionally comprising a step of forming a salt thereof.

2 . The method according to claim 1 , said method comprising a step of reacting a compound represented by formula III:

(wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group), a salt thereof, or a derivative thereof with aminourea or a salt thereof in water to produce the compound represented by formula IV or a salt thereof, and then a step of subjecting the resulting compound or a salt thereof to the step(s) according to claim 1 .

3 . The method according to claim 2 , said method comprising a step of subjecting the compound represented by formula IV or a salt thereof without isolation to the step(s) according to claim 1 .

4 . The method according to claim 3 , said method comprising a step of collecting the compound represented by formula IV or a salt thereof by filtration.

5 . The method according to claim 2 , said method comprising a step of reacting a compound represented by formula II:

(wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group) or a salt thereof with a glyoxalization reagent to produce the compound represented by formula III, a salt thereof, or a derivative thereof, and then a step of subjecting the resulting compound, a salt thereof, or a derivative thereof to the step(s) according to claim 2 .

6 . The method according to claim 5 , said method comprising a step of subjecting the compound represented by formula III, a salt thereof, or a derivative thereof without isolation to the step(s) according to claim 2 .

7 . The method according to claim 1 , wherein ring A is an optionally substituted monocyclic or bicyclic aryl group.

8 . The method according to claim 7 , wherein ring A is a monocyclic or bicyclic aryl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group.

9 . A method for producing a compound represented by formula V:

(wherein ring A represents an optionally substituted aryl group or an optionally substituted heteroaryl group and R B represents an optionally substituted aliphatic heterocyclic group) or a pharmaceutically acceptable salt thereof, said method comprising a step of producing the compound represented by formula I or a salt thereof by the method according to claim 1 , and then a step of producing the compound represented by formula V or a pharmaceutically acceptable salt thereof by a known method.

10 . The method according to claim 9 , wherein
ring A is an optionally substituted monocyclic or bicyclic aryl group; and R B is a group represented by formula VI:

(wherein X a represents CR 3a or N;
(i) when X a represents CR 3a , then
X b represents CHR 3 b and X c represents O or NR 4 ,
X b represents O and X c represents NR 4 , or
X b represents NR 4b and X c represents O, NR 4 , or CHR 3 ;

(ii) when X a represents N, then
X b represents CHR 3 b or C(═O) and X c represents NR 4 , or
X b represents NR 4b and X c represents CHR 3 ;
R 3a represents a hydrogen atom, a hydroxy group, an alkyl group, or an amino group;
R 3b and R 3c represent each a group independently selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkyl group;
R 4b and R 4c represent each a group independently selected from the group consisting of a hydrogen atom, an alkyl group, and a cycloalkyl group;
R 1 represents a hydrogen atom or an alkyl group;
R 2 represents

(i) an optionally substituted alkyl group,
(ii) an optionally substituted cycloalkyl group,
(iii) an optionally substituted aliphatic heterocyclic group,
(iv) an optionally partially hydrogenated and optionally substituted heteroaryl group, or
(v) a hydrogen atom, or
when X c represents NR 4c , then R 2 and R 4c are combined with each other at their terminals together with the nitrogen atom to which they are attached to form an aliphatic heterocyclic group optionally substituted with an optionally substituted alkyl group; and
the wavy line represents the point of attachment to the rest of molecule).

11 . The method according to claim 10 , wherein
ring A is a monocyclic or bicyclic aryl group optionally substituted with 1 to 3 group(s) independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group; R B is a group represented by formula VI; X a represents N; X b represents CHR 3b or C(═O); X c represents NR 4c ; R 3b represents a group independently selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkyl group; R 4c represents a group independently selected from the group consisting of a hydrogen atom, an alkyl group, and a cycloalkyl group; R 1 represents a hydrogen atom or an alkyl group; R 2 represents (i) an optionally substituted alkyl group, (ii) an optionally substituted cycloalkyl group, (iii) an optionally substituted aliphatic heterocyclic group, (iv) an optionally partially hydrogenated and optionally substituted heteroaryl group, or (v) a hydrogen atom, or
R 2 and R 4 are combined with each other at their terminals together with the nitrogen atom to which they are attached to form an aliphatic heterocyclic group optionally substituted with an optionally substituted alkyl group.

Assignees

• Mitsubishi Tanabe Pharma Corp

Inventors

• Yamagami Takafumi
• Yamasaki Souta
• Setsuta Tomofumi
• Sakakibara Ryo
• Matsumura Yosuke

Classifications

• C07D253/07 Primary

  with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title